RCS - Hemogenyx Pharma Plc - Invitation to Participate at DCNY Summit

Hemogenyx PharmaceuticalsAnnouncement

11/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250911:nRSK7852Ya&default-theme=true

RNS Number : 7852Y  Hemogenyx Pharmaceuticals PLC  11 September 2025

11 September 2025

Hemogenyx Pharmaceuticals plc

("Hemogenyx" or the "Company")

Hemogenyx Pharmaceuticals Invited to Participate at DCNY Summit

Hemogenyx Pharmaceuticals plc (LSE: HEMO), is pleased to announce that the
Company has been invited to participate and present at the upcoming DCNY
Summit, taking place in Washington, DC on 18 September 2025 and in New York on
22 September 2025.

The DCNY Summit is co-hosted by the Alliance Indus Foundation, together with
Congressional leaders, the Embassy of India, Saudi Vision Invest, and other
international partners, and is designed as a high-level forum connecting
Washington, DC and New York to bring together policymakers, investors,
corporate leaders, and innovators.

Hemogenyx will present its clinical progress and pipeline as part of the
Summit's curated company showcase. Previous Summit participants have
successfully secured significant growth capital, underscoring the Summit's
reputation as a catalyst for financing and partnerships.

Participation in the DCNY Summit provides Hemogenyx with a valuable platform
to:

·      Highlight recent clinical milestones, including the ongoing Phase
I clinical trial of its lead CAR-T cell therapy for acute myeloid leukemia
(AML);

·      Showcase the Company's broader therapeutic pipeline to an
audience of influential stakeholders;

·      Engage directly with investors, collaborators, and
decision-makers at the intersection of science, healthcare, and finance.

Dr. Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented:

"We are honored to have been invited to present Hemogenyx at the DCNY Summit.
This prestigious event convenes a remarkable group of global investors,
corporate leaders, and policymakers, and provides us with a unique opportunity
to highlight our progress and to engage with those who can help accelerate our
mission to transform the treatment of cancer."

Enquiries:

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

About DCNY Summit

The DCNY Summit (https://dcnysummit.org (https://dcnysummit.org) ) is an
annual high-level forum connecting Washington, DC and New York to bring
together policymakers, corporate leaders, investors, and innovators. It is
co-hosted by the Alliance Indus Foundation in partnership with Congressional
leaders, the Embassy of India, Saudi Vision Invest, and other global
organizations. The Summit serves as a platform for showcasing transformative
companies, fostering international collaboration, and catalyzing financing and
innovation across life sciences, healthcare, and technology sectors.

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City.

The Company is a clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as platform technologies that it uses as engines for novel
product development.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRALMMPTMTIBMBA